Treatment of HBV-related cirrhosis

References

• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis-B: summary of a clinical research workshop. Hepatology45, 1056–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Liaw YF. Prevention and surveillance of hepatitis-B virus-related hepatocellular carcinoma. Semin. Liver Dis.25, 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45, 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin. Liver Dis.26, 142–152 (2006).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis-B: special emphasison disease progression and prognostic factors. J. Hepatol.48, 335–352 (2008).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long term outcome of chronic B hepatitis in Caucasian patients: mortality after 25 years. Gut57, 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma: incidence and risk factors. Gastroenterology127, S35–S50 (2004).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis-B. J. Hepatol.50, 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis-B and advanced liver disease. N. Engl. J. Med.351, 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Manno M, Camma C, Schepis F et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology127, 756–763 (2004).
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis-B in children after e antigen seroclearance: final report of a 29 year longitudinal study. Hepatology43, 556–562 (2006).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis-B viral load. Gastroenterology130, 678–686 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis-B virus DNA level. JAMA295, 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Huo Ti, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis-B: a multivariate analysis in a longitudinal study. Eur. J. Gastroenterol. Hepatol.12, 687–693 (2000).
   PubMed Web of Science ®Google Scholar
• Park BK, Park YN, Ahn SH et al. Long term outcome of chronic hepatitis-B based on histological grade and stage. J. Gastroenterol. Hepatol.22, 383–388 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu YS, Chien RN, Yeh CT et al. Long term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis-B. Hepatology35, 1522–1527 (2002).
   PubMed Web of Science ®Google Scholar
• Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis-B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med.116, 829–834 (2004).
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis-B virus genotype on the long-term outcome of chronic hepatitis-B in Western patients. Gastroenterology123, 1848–1856 (2002).
   PubMed Web of Science ®Google Scholar
• Toan NL, Song LH, Kremsner PG et al. Impact of the hepatitis-B virus genotype and genotypes mixtures on the course of the liver disease in Vietnam. Hepatology43, 1375–1384 (2006).
   PubMed Web of Science ®Google Scholar
• Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis-B virus carriers with progressive liver diseases. Gastroenterology130, 1153–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis-B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis-B carriers. J. Infect. Dis.193, 1258–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis-B virus infection. Gastroenterology126, 1024–1029 (2004).
   PubMed Web of Science ®Google Scholar
• Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis-B in co-infected patients. J. Hepatol.44, S65–S70 (2006).
   PubMed Web of Science ®Google Scholar
• Puoti M, Cozzi-Lepri A, Arici C et al. Impact of lamivudine on the risk of liver-related death in 2041 HBsAg- and HIV-positive individuals: results from an inter cohort analysis. Antivir. Ther.11, 567–574 (2006).
   PubMed Web of Science ®Google Scholar
• Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environnemental factors: a systematic review of the epidemiologic evidence. Oncogene25, 3756–3770 (2006).
   PubMed Web of Science ®Google Scholar
• Bondini S, Kallman J, Wheeler A et al. Impact on non alcoholic fatty liver disease on chronic B hepatitis. Liver Int.27, 607–611 (2007).
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases risk of hepatocellular carcinoma in the United-States: a population based case control study. Gut54, 533–539 (2005).
   PubMed Web of Science ®Google Scholar
• Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene25, 3823–3833 (2006).
   PubMed Web of Science ®Google Scholar
• Hache C, Villeneuve J-P. Lamivudine treatment in patients with chronic hepatitis-B and cirrhosis. Expert Opin. Pharmacother.7, 1835–1843 (2006).
   PubMed Web of Science ®Google Scholar
• Wong DKH, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of a-interferon in patients with hepatitis-B e antigen-positive chronic hepatitis-B: a meta-analysis. Ann. Intern. Med.119, 312–323 (1993).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis-B. N. Engl. J. Med.352, 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis-B: a randomised trial. Lancet365, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GKK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis-B. N. Engl. J. Med.351, 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Niederau K, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon a for chronic hepatitis-B. N. Engl. J. Med.334, 1422–1427 (1996).
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Buti M et al. Peginterferon α-2b is safe and effective in AgHBe-positive chronic hepatitis-B patients with advanced fibrosis. Hepatology46, 388–394 (2007).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF et al.; Globe study group. Telbivudine versus lamivudine in patients with chronic hepatitis-B. N. Engl. J. Med.357, 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis-B e antigen-positive chronic hepatitis-B. N. Engl. J. Med.348, 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis-B. N. Engl. J. Med.354, 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis-B. N. Engl. J. Med.359, 2442–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis-B for up to 5 years. Gastroenterology131, 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok A et al. Entecavir versus lamivudine for patients with HBe Ag-negative chronic hepatitis-B. N. Engl. J. Med.354, 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Serpaggi J, Carnot F, Nalpas B et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum. Pathol.37, 1519–1526 (2006).
   PubMed Web of Science ®Google Scholar
• Farci P, Roskams T, Chessa L et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology126, 1740–1749 (2004).
   PubMed Web of Science ®Google Scholar
• Mallet VO, Dhalluin-Venier V, Verkarre V et al. Reversibility of cirrhosis in HIV/HBV co-infection. Antivir. Ther.12, 279–283 (2007).
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis.45, 804–817 (2005).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis-B patients. Gastroenterology133, 1445–1451 (2007).
   PubMed Web of Science ®Google Scholar